← Back to Analyst Consensus 
SGMT Buy
Sagimet Biosciences Inc.
Current Price —
Implied Upside —
Analysts 19
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 4 reiterations from 4 firms
Next Earnings
Nov 12, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 2, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Oct 1, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Oct 1, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Sep 9, 2026 | Barclays | upgrade | Equal-Weight → Overweight | — | 53% |
| Sep 9, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Aug 25, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 14, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Aug 12, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| May 19, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| May 4, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 29, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 11, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 3, 2026 | Guggenheim | initiate | — → Buy | $27 | 52% |
| Feb 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $29 | 44% |
| Jan 28, 2026 | Barclays | initiate | — → Equal-Weight | $8 | 53% |
| Nov 14, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $35 | 47% |
| Oct 22, 2025 | Clear Street | initiate | — → Buy | $29 | 48% |
| Oct 2, 2025 | Canaccord Genuity | maintain | Buy → Buy | $28 | 48% |
| Aug 11, 2025 | Wedbush | initiate | — → Outperform | $28 | 58% |
| Jul 24, 2025 | Canaccord Genuity | initiate | — → Buy | $28 | 48% |
| Jun 6, 2025 | Jones Trading | maintain | Buy → Buy | $27 | 50% |
| Mar 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Mar 11, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jan 27, 2025 | Jones Trading | initiate | — → Buy | $42 | 50% |
| Dec 6, 2024 | Oppenheimer | initiate | — → Outperform | $30 | 52% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Nov 12, 2024 | UBS | initiate | — → Buy | $12 | 54% |
| Oct 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Oct 2, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Aug 15, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $32 | 53% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jul 1, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $6 | 54% |
| Jun 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jun 7, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $48 | 53% |
| Jun 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| May 24, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $48 | 53% |
| May 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| May 16, 2024 | Goldman Sachs | maintain | Buy → Buy | $23 | 54% |
| May 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| May 2, 2024 | HC Wainwright & Co. | initiate | — → Buy | $32 | 44% |
| Mar 26, 2024 | Goldman Sachs | maintain | Buy → Buy | $27 | 54% |
| Mar 25, 2024 | Leerink Partners | initiate | — → Outperform | $26 | 51% |
| Feb 7, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $46 | 53% |
| Jan 23, 2024 | Goldman Sachs | maintain | Buy → Buy | $37 | 54% |
| Jan 23, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $47 | 53% |
| Jan 22, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $47 | 53% |
| Dec 5, 2023 | JMP Securities | reiterate | Market Outperform → Market Outperform | $31 | 53% |
| Aug 8, 2023 | TD Cowen | initiate | — → Outperform | $0 | 54% |
| Aug 8, 2023 | Piper Sandler | initiate | — → Overweight | $67 | 54% |
Price Target Trend
Apr 21, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days